Scarica l'app Stockscreener
65.92
1.20%
0.885
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
Assessing PTC Therapeutics (PTCT) Valuation After Encouraging New Huntington’s Disease Data - Yahoo Finance
Horizon Investments LLC Takes $3.06 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
How The PTC Therapeutics (PTCT) Story Is Shifting With Sephience And Franchise Pressures - Yahoo Finance
PTC Therapeutics stock sinks as pivotal data fails to calm sellers - MSN
Three PTC investor conference webcasts start May 12 and stay up 30 days - Stock Titan
Vanguard Group Inc. Purchases 514,204 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics to Participate in Upcoming Investor Conferences - PR Newswire
UBS Group AG Has $73.28 Million Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
(PTCT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Hussman Strategic Advisors Inc. Has $1.91 Million Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (PTCT) Reports Positive Huntington’s Disease Trial Results - Insider Monkey
Is PTC Therapeutics a Better Buy Than Eli Lilly? - Trefis
PTC Therapeutics Hits Day Low of $63.76 Amid Price Pressure - Markets Mojo
MSN Money - MSN
PTC Therapeutics (PTCT) Is Down 5.1% After New Votoplam Huntington’s Data And Novartis Milestone - Yahoo Finance
PTC Therapeutics Stock Sinks As Pivotal Data Fails To Calm Sellers - Sahm
Vanguard holds 4.28M PTC Therapeutics (NASDAQ: PTCT) shares - Stock Titan
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Gastroparesis Market: Investment-Ready Growth Trends to 2034 – DelveInsight | Vanda Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma - Barchart.com
Gastroparesis Market: Investment-Ready Growth Trends to 2034 - openPR.com
PTC Therapeutics (PTCT) Expected to Announce Earnings on Thursday - MarketBeat
PTC Therapeutics Stock To $84? - Trefis
Is 12.3% Fall In PTC Therapeutics (PTCT) Stock A Buying Opportunity? - Trefis
PTC Therapeutics Drops 8.3% Amid Sector-Wide Selling - AlphaStreet
PTC Therapeutics, Inc. (PTCT) Discusses 24-Month Interim Results of PIVOT-HD Long-Term Extension Study of Votoplam in Huntington's DiseaseSlideshow (NASDAQ:PTCT) 2026-04-29 - Seeking Alpha
Vanguard (NASDAQ: PTCT) holds 4.87M PTC Therapeutics shares - Stock Titan
PTC Therapeutics (NASDAQ:PTCT) Trading Down 8.5%Here's What Happened - MarketBeat
BofA Securities Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Announces Target Price $93 - Moomoo
AA meeting of minds as PTC, Novartis push votoplam in HD - BioWorld News
Is PTC Therapeutics (PTCT) Pricing Reflect Recent Pipeline Progress And Volatile Share Performance - simplywall.st
PTC Therapeutics, Inc. $PTCT Shares Sold by Pictet Asset Management Holding SA - MarketBeat
M&T Bank Corp Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics Shares 24-Month Votoplam Data Showing Dose-Linked Huntington’s Slowing Signals - MarketBeat
PTCT: Promising Results in Huntington's Disease Treatment Study - GuruFocus
PTC Therapeutics : PIVOT-HD Long-Term Extension Study Topline Results Call – April 28, 2026 - marketscreener.com
PTC Therapeutics Reports Positive 24-Month Votoplam Data - TipRanks
PTC Therapeutics (NASDAQ: PTCT) shows 52% slowing in HD study - Stock Titan
PTC reports votoplam slowed Huntington’s disease progression by 52% - Investing.com Canada
PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam - ChartMill
PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study - ChartMill
Teachers Retirement System of The State of Kentucky Buys 19,000 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
Huntington’s Disease Pipeline Set for Breakthrough Transformation by 2026 with 20+ Therapies and Advancing Gene-Silencing Innovations | DelveInsight - Barchart.com
PTC Therapeutics Inc (PTCT) - MSN
Q3 2025 PTC Therapeutics Inc Earnings Call Transcript - GuruFocus
PTC Therapeutics projects FY26 product revenue between $700M to $800M - MSN
PTC Therapeutics, Inc. $PTCT Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Abacus FCF Advisors LLC Makes New $5.76 Million Investment in PTC Therapeutics, Inc. $PTCT - MarketBeat
Assessing PTC Therapeutics (PTCT) Valuation After Recent Share Price Swings And Pipeline Progress - Sahm
Roche gets EU nod for Evrysdi's expanded label in spinal muscular atrophy - MSN
PTC Therapeutics Shares Drop After FDA Rejects Vatiquinone Application - MSN
PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026 - Nasdaq
PTC Therapeutics CEO Matthew Klein sells $202,093 in stock - Investing.com UK
PTC Therapeutics CEO Matthew Klein sells $202,093 in stock By Investing.com - Investing.com India
Matthew Klein Sells 2,850 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
Automatic tax sale trims PTC Therapeutics (PTCT) CEO stake slightly - Stock Titan
TD Cowen Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Maintains Target Price $75 - Moomoo
0.78%
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):